Cargando…

ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer

BACKGROUND: In colorectal cancer (CRC), BRAF mutations influence tumour progression. In mismatch repair-deficient (dMMR) tumours, BRAF mutations are associated with a good prognosis, whereas in MMR-competent tumours, they are detrimental. The differential expression of the downstream MAPK pathway me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roseweir, Antonia K., Halcrow, Elaine S., Chichilo, Sergey, Powell, Arfon GMT, McMillan, Donald C., Horgan, Paul G., Edwards, Joanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070918/ https://www.ncbi.nlm.nih.gov/pubmed/29988110 http://dx.doi.org/10.1038/s41416-018-0174-y

Ejemplares similares

Reply to comment of “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”
por: Roseweir, Antonia K., et al.
Publicado: (2018)

Relationship between tumour PTEN/Akt/COX-2 expression, inflammatory response and survival in patients with colorectal cancer
por: Roseweir, Antonia K., et al.
Publicado: (2016)

Comment on “ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer”
por: Uzunparmak, Burak, et al.
Publicado: (2018)

Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment
por: Park, James H, et al.
Publicado: (2016)

Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
por: Roseweir, Antonia K, et al.
Publicado: (2020)

The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer
por: van Wyk, Hester C., et al.
Publicado: (2019)

Undergraduate medical textbooks do not provide adequate information on intravenous fluid therapy: a systematic survey and suggestions for improvement
por: Powell, Arfon GMT, et al.
Publicado: (2014)

The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer
por: Dreyer, Stephan B., et al.
Publicado: (2016)

A case of septicaemic anthrax in an intravenous drug user
por: Powell, Arfon GMT, et al.
Publicado: (2011)

The top 100 manuscripts in emergency cardiac surgery. Potential role in cardiothoracic training. A bibliometric analysis
por: Karsan, Rickesh B., et al.
Publicado: (2019)

P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b
por: Naffa, Randa, et al.
Publicado: (2020)

High expression of STAT3 within the tumour‐associated stroma predicts poor outcome in breast cancer patients
por: Morrow, Elizabeth, et al.
Publicado: (2023)

The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer
por: Alexander, Peter G., et al.
Publicado: (2020)

Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways
por: Xie, Jingyi, et al.
Publicado: (2023)

Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer
por: Patel, Meera, et al.
Publicado: (2022)

BIOL-05. MAPK PATHWAY INHIBITION SENSITIZES TO IMMUNOTHERAPY IN BRAF-MUTANT GLIOMAS
por: Park, Jong-Whi, et al.
Publicado: (2021)

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer
por: Pickles, Oliver J., et al.
Publicado: (2020)

Aluminum Nanoparticles Induce ERK and p38MAPK Activation in Rat Brain
por: Kwon, Jung-Taek, et al.
Publicado: (2013)

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation
por: Lochhead, Pamela A., et al.
Publicado: (2016)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer
por: Al‐Badran, Sara SF, et al.
Publicado: (2020)

PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas
por: Lu, Hezhe, et al.
Publicado: (2017)

Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway
por: Gillies, Taryn E, et al.
Publicado: (2020)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
por: Han, Shujun, et al.
Publicado: (2018)

Purinergic calcium signaling drives drug tolerance through ERK reactivation in BRAF-mutant melanoma
por: Stauffer, Philip E., et al.
Publicado: (2023)

Protease Allergens Induce the Expression of IL-25 via Erk and p38 MAPK Pathway
por: Yu, Hak Sun, et al.
Publicado: (2010)

A Specific Oligodeoxynucleotide Promotes the Differentiation of Osteoblasts via ERK and p38 MAPK Pathways
por: Hou, Xu, et al.
Publicado: (2012)

P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17
por: Tan, Qi, et al.
Publicado: (2017)

Bakuchiol Suppresses Inflammatory Responses Via the Downregulation of the p38 MAPK/ERK Signaling Pathway
por: Lim, Hye-Sun, et al.
Publicado: (2019)

Fit for Cancer Treatment: a prospective feasibility study of primary care initiated prehabilitation for patients with suspected cancer
por: Barlow, Rachael C, et al.
Publicado: (2018)

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors
por: Lee, Kye Hwa, et al.
Publicado: (2020)

The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors
por: Delmas, Audrey, et al.
Publicado: (2015)

Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma
por: Zhao, Kun, et al.
Publicado: (2020)

Co-inhibition of SMAD and MAPK signaling enhances (124)I uptake in BRAF-mutant thyroid cancers
por: Luckett, Kathleen A, et al.
Publicado: (2021)

MAPK-ERK Pathway
por: Park, Jong-In
Publicado: (2023)

The relationship between members of the canonical NF-κB pathway, components of tumour microenvironment and survival in patients with invasive ductal breast cancer
por: Bennett, Lindsay, et al.
Publicado: (2017)

Sesamin stimulates osteoblast differentiation through p38 and ERK1/2 MAPK signaling pathways
por: Wanachewin, Orawan, et al.
Publicado: (2012)

Effect of Repeated Electroacupuncture Intervention on Hippocampal ERK and p38MAPK Signaling in Neuropathic Pain Rats
por: Wang, Jun-ying, et al.
Publicado: (2015)

Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs
por: Barreto, Rafael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bl2i529uvuc5gne1squ0qs5kap